Form 4: Neurocrine CSO Gifts Shares in Pre-Planned Transaction
Insider Transaction Report
Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, gifted 1,470 shares of common stock in a pre-planned transaction.
Summary
- Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences Inc. (NBIX), disposed of 1,470 shares of common stock.
- The transaction, a gift/charitable contribution, was effective on September 3, 2025.
- No value was received for the gifted shares, as it was not a market transaction.
- Following this transaction, Jude Onyia beneficially owns 13,703 shares of Neurocrine Biosciences common stock.
- The disposition was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Sentiment
Score: 5
Explanation: A gift of shares by an executive, especially when pre-planned, is generally a neutral event for the company's operational performance. While it reduces insider ownership, the structured nature mitigates any negative perception.
Positives
- The transaction was pre-planned under a Rule 10b5-1(c) plan, indicating a structured approach to share disposition and reducing concerns about opportunistic trading.
Negatives
- Chief Scientific Officer Jude Onyia reduced direct beneficial ownership by 1,470 shares.
Future Outlook
No forward-looking statements or guidance were provided in this filing.
Management Comments
- This transaction represents a gift/charitable contribution effective September 3, 2025.
- This is not a market transaction, thus no price has been reported.
- No value was received for the gifted shares.
Industry Context
This insider transaction is a routine disclosure and does not provide specific insights into broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | Transaction executed under a Rule 10b5-1(c) plan, demonstrating adherence to pre-arranged trading plans designed to avoid insider trading allegations. | 09/03/2025 | Enhances transparency and reduces perception of opportunistic insider trading. |
Stakeholder Impact
- Shareholders: A minor reduction in direct insider ownership, but the pre-planned nature of the gift under a 10b5-1 plan suggests a non-opportunistic disposition, which is generally viewed neutrally.
Key Dates
| Date | Description |
|---|---|
| 09/03/2025 | Effective date of the gift/charitable contribution of common stock. |
| 09/04/2025 | Date the Form 4 was signed by the attorney-in-fact for Jude Onyia. |
Recommendation
holdThe filing reports a routine, pre-planned gift of shares by a Chief Scientific Officer. This type of insider transaction is generally not indicative of the company's fundamental performance or future prospects and does not warrant a change in investment thesis based solely on this event.
Keywords
NBIX, Neurocrine Biosciences, insider transaction, Form 4, stock gift, Jude Onyia, Chief Scientific Officer, common stock, 10b5-1 plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.